Author

G. Girolomoni

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis).

INTRODUCTION Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 wee...

L. Potestio, S. Corrao, L. Mastorino et al. · Dermatologic Therapy · 0 citations

Open access Sep 2026

Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.

While targeted therapies have reshaped the clinical management of immune-mediated inflammatory diseases (IMIDs), primary non-response remains a major obstacle for many patients. Combining two targeted therapies is an emerging strategy to overcome this therapeutic ceiling, but the number of possible drug pairs makes pri...

S. Martínez-Mateu, Y. Guillén, Edgar Angelats et al. · Cell Reports Medicine · 1 citation